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Sally Robinson5, Tim Sangster6, Susan Sparrow7, Neil Spooner8 and Amanda Wilson5
Toxicokinetic analysis is an essential part of nonclinical drug development. Advances in bioanalytical
techniques have opened up the potential to use smaller sample volumes (microsamples) to assess drug
exposure in blood, plasma and/or serum. Microsampling can increase the amount of nonclinical safety
information available, improve its validity by linking toxic effects to drug exposure in individual
animals and represents the most significant opportunity to reduce animal use in toxicology studies in
the short term. In May 2013, a workshop was held with 80 delegates from 33 companies with the aim of
sharing information and knowledge on microsampling technologies. This article covers the discussions
at the workshop, current practice in the industry, regulatory experiences and the future direction of
microsampling across drug development.
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During the development of new drugs, noncli-
nical safety studies are carried out in rodent and
non-rodent species to identify and characterise
adverse effects and facilitate risk assessment for
clinical studies. Toxicokinetic (TK) data are an
essential component of these studies and are
used to correlate circulating drug concentrations
(exposure) with pathology or functional effects,
the primary endpoints in safety assessment
studies. The matrix for determining drug con-
centration could be blood, plasma or serum.528 www.drugdiscoverytoday.com 1359-6Exposure–response correlations in animals are
subsequently used to define a safe starting dose
level in the clinic to set stopping rules and avoid
harmful drug accumulation or interactions.
Requirements for safety assessment and TK are
described in international regulatory guidelines
issued by the International Conference on Har-
monisation (ICH) [1]. The guidelines indicate that
TK information should be obtained to provide
proof of drug exposure during the period of
dosing but do not dictate how exposure is
measured, thereby enabling technological
innovations in the bioanalysis of TK samples. TK
data are used in a number of ways. For example,
it is important to know if there is accumulation
over time or if the active drug is clearing dif-
ferently after repeated drug doses, as might
happen with metabolic induction, immunogenic446/06  2014 The Authors. Published by Elsevier Ltd. Open accessclearance or intoxication of target organs
involved in clearance. Exposures are also
examined across dose levels to determine
whether drug concentrations increase propor-
tionally with the delivered drug dose or if there
are irregularities as a result of altered drug
absorption or compartmental saturation. Dif-
ferences in exposure between males and
females can also be investigated. All of this
information is important for decision making on
dosing routes and frequencies in a given patient
population.
Individual TK blood samples are typically
required at four to six timepoints (within a 24
hour period for small-molecule drugs and over
several days for biopharmaceutical drugs) on at
least two occasions in each nonclinical safety
study (Table 1). Conventionally, a blood volume http://dx.doi.org/10.1016/j.drudis.2014.01.002 under CC BY license.
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TABLE 1
An example study design for toxicokinetic (TK) analysis on a one month good laboratory
practice (GLP) rat study
Animal number Sampling timepoint
#1 #2 #3 #4 #5 #6
1 x x x
2 x x x
3 x x x
4 x x x
5 x x x
6 x x x
7 x x x
8 x x x
9 x x x
10 x x x
n = 5 n = 5 n = 5 n = 5 n = 5 n = 5
All the main study animals are sampled. There are a total of ten animals per sex per group (80 rats). TK profiles are made up
from composite samples as follows: six timepoints (#1 to #6), three samples per animal (see x in rows), five samples per
timepoint (see x in columns). This gives a total of 30 TK samples per sex per group. Previously 18 samples per sex per group
were taken sampling satellite animals (an additional 18 rats).
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circulating drug concentrations. In rodent stu-
dies, this relatively large volume of blood could
cause anaemia or other secondary effects such
as bone marrow and haematological changes,
which would confound interpretation of primary
drug effects. Therefore, these blood samples are
often taken from satellite animals, which are
added to the study solely for TK purposes. This
can lead to a large increase in the number of
rodents required for a typical study. For example,
for a typical 4 week repeat oral dose rat study an
additional three to nine satellite animals per
dose group per sex might be required
(depending upon the sample volume and
number of timepoints required) in addition to
ten main study animals. Further, the use of TK
satellite animals means that there is no way to
correlate drug levels directly with drug action,
because pathology or functional effects are
measured in the main study animals and drug
exposure is measured in similarly dosed TK
satellite animals. The blood, plasma or serum is
typically analysed by either LC–MS/MS, or
immunoassay to determine levels of drug and, in
some cases, associated metabolites, anti-drug
antibodies (ADAs) or pharmacodynamic (PD)
endpoints. The focus of this paper is on the
evaluation of small molecules in rodents because
this is where current microsampling efforts are
directed and are likely to have the biggest
impact. However, the benefits and use of
microsampling are not limited to this area. It is
often assumed that the rodent is not a relevant
model for ‘biologic’ drugs such as monoclonalantibodies (mAbs), but the screening for potency
and use of the rodent for mAbs is on the rise and
expected to increase further. Additionally, blood
sample volume in rodents and larger species,
such as non-human primates, is particularly
challenging for biologics because these often
require sampling for determination of TK and
ADAs as well as monitoring of PD endpoints
[ICHS6 (R1)].
The collection of samples for TK analysis using
conventional rodent study designs (i.e. with
satellite animals) has been identified as the
largest influence on rodent numbers used in
regulatory toxicology studies [2]. Therefore,
microsampling represents the most significant
opportunity to reduce rodent use in toxicology
studies in the near term. Advances in the sen-
sitivity of bioanalytical techniques, particularly
LC-MS/MS, now provide the capability to con-
duct analysis with much smaller volume sam-
ples, around 25–30 ml; these are termed
‘microsamples’. A number of the approaches
currently in use are illustrated in Fig. 1 [3–6]. The
potential benefits of microsampling are just
beginning to be realised in drug development
and could have profound effects on regulatory
safety assessment studies. This article discusses
the barriers to the more widespread adoption of
microsampling and outlines the ways forward
based on the output from a recent meeting
organised by the NC3Rs, an independent
scientific organisation that drives innovative
technologies to replace, reduce and refine
the use of animals in research and safety
testing.Benefits
There are scientific, business and animal welfare
benefits to employing microsampling in asso-
ciation with sensitive assay technology. From a
scientific perspective, TK sampling from main
study animals allows direct correlation of func-
tional and/or pathological changes with con-
centration of test article in the individual animal’s
blood. This allows a clear connection between
drug exposure and drug action, as is currently
the norm in larger preclinical species and human
patients but rare in standard rodent studies.
Microsampling in all species can also provide
scope for the use and characterisation of a
broader array of biomarkers, enabling better
insight into pharmodynamic effects. The aim is
that these endpoints will facilitate better
research translation and help to mitigate risks in
clinical trials through improved clinical moni-
toring. From a business perspective, when
reduced numbers of satellite animals or none at
all are used, less compound and resource (dos-
ing, handling and care) is needed and this can
potentially lead to notable cost savings for these
studies. There is also significant potential to
refine blood sampling procedures across all
species to make collection of samples quicker
and less stressful for the animal than conven-
tional sampling. In addition to improved welfare,
this will deliver better science in that there would
be less disturbance to critical physiological
parameters (e.g. heart rate and respiratory rate).
These wide-ranging incentives have contributed
to making microsampling a hot topic of debate
within the industry.
The challenge
In May 2013 in central London, the NC3Rs hosted
a workshop for 80 delegates from 33 companies
and representatives from regulatory bodies to
share information and knowledge on the novel
microsampling technologies being used and
what the barriers were to further implementa-
tion. All companies provided information on
their current use of, and future plans for,
microsampling within drug development
through a pre-meeting questionnaire. In identi-
fying barriers to the uptake of microsampling
techniques, it was established that there are two
primary aspects: (i) functional and clinical
pathology evaluation and (ii) approaches to
bioanalysis and TK. To date, much of the debate
has centred on bioanalytical methods and
whether the assay will deliver enough sensitivity
with the small samples available and it has been
established that many of the bioanalytical issues
are surmountable. Much less attention has been
given to the real or perceived issues regardingwww.drugdiscoverytoday.com 529
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FIGURE 1
A selection of different approaches used for microsampling to obtain toxicokinetic samples from rodents
in safety assessment studies. (a) Dried blood spots derived from blood collected in a capillary, (b) fixed
volume of blood collected in capillary added to fixed volume of water in a tube, (c) hematocrit capillary
sealed at one end, centrifuged, scored and broken and plasma obtained in another microcapillary, (d)
plasma separation capillary with sealable porous plug, centrifuged and plasma decanted to small tube.
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clinical pathological endpoints measured in
safety assessment studies in animals. This was
identified as the major barrier for uptake of
microsampling at the London workshop. There
was unanimous opinion among participants
towards the rapid implementation of micro-
sampling in nonregulatory and regulatory safety
assessment studies in all companies and for
robust mechanisms to be put in place to enable
this to happen. This article covers current prac-
tice in the industry, regulatory experience and
the potential future direction of microsampling
across drug development.
The current environment
Although there is a lot of anecdotal evidence
that suggests companies are using microsam-
pling in drug development, there has been
little sharing to date of the current practice.530 www.drugdiscoverytoday.comInformation was shared from the participating
companies at the workshop through a pre-
meeting questionnaire, posters and speaker
presentations. The pre-meeting questionnaire
showed that companies use the term ‘micro-
sample’ for a range of volumes across all species
from less than 25 ml to over 100 ml. The defini-
tion of a microsample can also differ between
species, particularly rodents and non-rodents.
The consensus of the meeting was that a
microsample should ideally be no more than
50 ml whole blood. Most companies sampled
between four and six timepoints per TK profile in
individual rodents. Owing to the limited total
volume of blood available in the mouse, satellite
animals or increased main study group size
might still be required for studies in this species
when microsampling is employed, but the
overall numbers of rodents used can be signif-
icantly reduced. From a general perspective, wetblood, plasma and serum microsamples are
exactly the same as conventional volume sam-
ples of the same matrix, only smaller.
We found that, although there is widespread
use of microsampling in discovery, dose finding
and pharmacokinetic (PK) studies, this is not
translated into use in regulatory studies (Fig. 2a).
Only three companies have experience of reg-
ulatory acceptance of good laboratory practice
(GLP) studies that include microsampling. In total
81% of companies who responded (22/27) are
currently using microsampling techniques in
drug development and the remaining 19%
would like to start to implement them. The
majority of companies (17/22) use microsam-
pling for small molecules and the remainder use
microsampling for small and large molecules.
The most commonly used technique for analysis
is small volume plasma, but dried blood spots
and small volume blood are also used frequently.
Dry plasma spots and small volume serum are
less frequently used (Fig. 2b).
Many companies have used microsampling
techniques to sample from satellite animals. By
using microsampling rather than conventional
sampling the number of satellite mice could be
substantially reduced and their use in rat stu-
dies potentially eliminated. However, the full
scientific potential of microsampling, to relate
exposure to toxicological findings in individual
animals, is not achieved unless TK samples are
obtained from main study animals. Concerns
were identified at the workshop that TK sam-
pling from main study animals will affect
parameters that are routinely measured in
regulatory safety assessment studies, such as
clinical pathology, pathology and functional
observations on the major organ systems [e.g.
on the central nervous system (CNS)] and this
was seen as the major barrier to the wide-
spread uptake of microsampling techniques.
One piece of data that has been published
shows that blood volumes of up to 145 ml
collected from rats two days before clinical
pathology assessment do not affect the quality
of those data but a total of 1250 ml leads to
effects on red blood cell parameters, which
reflect the loss of blood [4]. Despite these
concerns, nearly 50% of companies have used
main study animals for microsampling at least
once. There is also a question when satellite
animals are not included in studies as to
whether TK parameters should be generated as
full serial profiles from individual animals or as
a composite profile from a number of different
animals and if control animals should be
sampled in an identical manner to those given
the drug.
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FIGURE 2
(a) The number of companies employing microsampling in non-Good Laboratory Practice (GLP) (discovery, dose range finding and pharmacokinetics) and GLP
(general toxicology, safety pharmacology and genetic toxicology) studies. (b) Number of companies using different types of wet and dry microsampling analysis
for small and large molecules. Abbreviation: SV, small volume.
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The regulatory feedback received at the work-
shop was that if scientific confidence in the
method could be demonstrated then this would
feed through to regulatory acceptance. There
are limited companies with experience of reg-
ulatory submissions but those who have used
microsampling in GLP studies have had no issues
raised. However, there is still a perception in the
industry that there could be regional differences
in regulatory viewpoints. All questions that
companies have received from regulators have
not been related to liquid or preclinical micro-
sampling but have generally been about clinical
sampling using Dried Blood Spot (DBS) techni-
ques. Attendees at the workshop identified anumber of questions that will probably be
addressed at the ICH level later in the year.
Recently an ICH Safety Topic Recommendation
working group was set up to ‘improve predic-
tivity of nonclinical safety testing by imple-
mentation of innovative approaches into
regulatory toxicology requirements’. Microsam-
pling has also been identified as a key topic for
this group and it is intended that the cross-
company initiative described in this article will
provide a valuable evidence base to contribute
to this ICH activity.
Future direction of microsampling
Information collected from major pharmaceuti-
cal and biotechnology companies and contractresearch organisations illustrates the widespread
interest in, and increasing uptake of, micro-
sampling technologies in drug development. An
increase in the use of microsampling for large
molecules brings different, additional challenges
in bioanalysis. With biologics there is a similar
need to relate TK to toxicity outcomes and also
to integrate this with an assessment of PD and
immunogenicity (ADA formation), all of which
require blood samples to be taken. This will be
an important area as the biologicals pipeline and
investment into biosimilars continue to increase.
Although the immediate need for implementa-
tion of microsampling is in rodents, the use of
microsampling for larger non-rodent species is
also likely to increase in the future. This will openwww.drugdiscoverytoday.com 531
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TABLE 2
Illustrative example designs: conventional sampling vs microsampling
Study type Conventional design with satellite animals Microsampling design Animal reduction
Dose range finding rat 3M + 3F per group, plus 3M + 3F per group for TK sampling 3M + 3F per group 50%
Typical numbers = 48 Typical numbers = 24
One month GLP toxicity
study rat
10M + 10F per group plus 3M + 3F per group for TK sampling 10M + 10F per group 23%
Typical numbers = 104 Typical numbers = 80
Three month GLP toxicity
study mouse
10M + 10F per group plus 6M + 6F per group for
TK sampling at beginning and end of study
10M + 10F per group 50%
Typical numbers = 158 Typical numbers = 80
Study design comparison between conventional studies and microsampling studies for rats during drug development. The number of male (M) and female (F) main study animals and
satellite animals are shown. The reduction in animal use ranges from 23% to 50% depending on the numbers of satellite animals used and this differs between organisations and studies.
Abbreviations: GLP, good laboratory practice; TK, toxicokinetics.
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cedures, including accessing less-invasive sam-
pling sites, thus improving animal welfare. It will
also enable an increase in the number of mea-
sured endpoints in blood samples, particularly
for biomarkers.
The overall direction of microsampling in the
pharmaceutical industry will be towards the use
of main study animals to generate TK profiles for
GLP safety assessment studies as well as in early
discovery and non-GLP studies. The primary
hurdle is the limited availability of published
data to address whether microsampling from
main study animals compromises key toxicolo-
gical endpoints. The majority of companies
attending the workshop had data they were
willing to share as part of a larger initiative to
generate an evidence base to support the
change in practice. The consensus agreed at the
workshop was to establish (through the NC3Rs) a
framework for data sharing and to publish a
consolidated evidence base. This would be used
as a basis for discussions with international
regulatory bodies.
Whereas immediate benefits on the wide-
spread application of microsampling are likely to
be on the reduction and/or removal of satellite
animals used to assess PK, TK and PD, meeting
attendees identified that blood sampling
volumes for clinical pathology are also signifi-
cant. Currently, these assessments are performed
using equipment designed for human clinical
sample analysis of relatively large volumes,
which in itself impacts the ability to use main
study animals for additional assessments. Con-
sequently, there exist opportunities for innova-
tive approaches to reduce blood volumes
sampled for clinical pathology especially for532 www.drugdiscoverytoday.comthose studies in which microsampling might not
sufficiently reduce blood sampling burden.
Concluding remarks
There are huge benefits for pharmaceutical,
biotechnology and contract research organisa-
tions to work together with regulators to
improve drug development through the use of
microsampling technologies. Microsampling
represents a fundamental opportunity to refine
blood sampling procedures, substantially reduce
animal use in safety assessment studies and
enhance scientific and business processes. There
is currently interest in this topic at the ICH level.
Regulatory clarification alongside change in
company practice will support accelerated
translation of scientific innovation into regula-
tory practice. There is a realistic potential to
reduce rodent numbers on an individual GLP
safety assessment study by almost 50% for mice
and rats (Table 2). In the future, with the accu-
mulated evidence base, the aim is that the use of
mice could be reduced further still, possibly by
up to 75% from some current designs. This
report provides insight into the current and
future direction for microsampling and supports
the widespread use of the technology, which is
on the verge of shaping the regulatory safety
assessment environment of the future.
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